Geron Drug Patent Portfolio
Geron owns 1 orange book drug protected by 6 US patents Given below is the list of Geron's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12171778 | Methods of treating myelodysplastic syndrome | 16 Jun, 2039 | Active |
| US12442000 | Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms | 15 Mar, 2033 | Active |
| US9375485 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | 15 Mar, 2033 | Active |
| US7494982 | Modified oligonucleotides for telomerase inhibition | 27 Dec, 2026 | Active |
| US9388415 | Modified oligonucleotides for telomerase inhibition | 09 Sep, 2026 | Active |
| US9388416 | Modified oligonucleotides for telomerase inhibition | 09 Sep, 2026 | Active |
Latest Legal Activities on Geron's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Geron.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Dispatch to FDC | 22 Sep, 2025 | US12442000 |
| Application Is Considered Ready for Issue | 22 Sep, 2025 | US12442000 |
| Issue Fee Payment Received | 18 Sep, 2025 | US12442000 |
| Issue Fee Payment Verified | 18 Sep, 2025 | US12442000 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US9388415 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US9388416 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US7494982 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US9375485 |
| Information Disclosure Statement (IDS) Filed | 19 Aug, 2025 | US9388415 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US7494982 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US9388416 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US9375485 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US9388415 |
| Information Disclosure Statement (IDS) Filed | 19 Aug, 2025 | US9388416 |
| Information Disclosure Statement (IDS) Filed | 19 Aug, 2025 | US9375485 |
Geron's Family Patents
Geron Drug List
Given below is the complete list of Geron's drugs and the patents protecting them.
1. Rytelo
Rytelo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12171778 | Methods of treating myelodysplastic syndrome |
16 Jun, 2039
(13 years from now)
| Active |
| US12442000 | Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms |
15 Mar, 2033
(6 years from now)
| Active |
| US9375485 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
15 Mar, 2033
(6 years from now)
| Active |
| US7494982 | Modified oligonucleotides for telomerase inhibition |
27 Dec, 2026
(8 months from now)
| Active |
| US9388415 | Modified oligonucleotides for telomerase inhibition |
09 Sep, 2026
(5 months from now)
| Active |
| US9388416 | Modified oligonucleotides for telomerase inhibition |
09 Sep, 2026
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rytelo's drug page